A class action lawsuit has been filed against ADMA Biologics (NASDAQ: ADMA), alleging violations of §§10(b) and 20(a) of the Securities Exchange Act and Rule 10b-5. The headline raises modest legal risk for the company, which can pressure the stock via uncertainty around potential liabilities and disclosures.
A class action lawsuit has been filed against ADMA Biologics (NASDAQ: ADMA), alleging violations of §§10(b) and 20(a) of the Securities Exchange Act and Rule 10b-5. The headline raises modest legal risk for the company, which can pressure the stock via uncertainty around potential liabilities and disclosures.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly negative
Sentiment Score
-0.20
Ticker Sentiment
